Table 2.
From aripiprazole to the βarrestin-biased D2 agonists96
![]() | ||||
---|---|---|---|---|
Compound | D2 cAMP EC50 (nM) | D2 cAMP Emax (%) | D2 βarr2 EC50 (nM) | D2 βarr2 Emax (%) |
5 | 1.0 | 51 | 4.0 | 62 |
6 | Inactive | <20 | 1.6 | 47 |
7 | Inactive | <20 | 50 | 97 |
From aripiprazole to the βarrestin-biased D2 agonists96
![]() | ||||
---|---|---|---|---|
Compound | D2 cAMP EC50 (nM) | D2 cAMP Emax (%) | D2 βarr2 EC50 (nM) | D2 βarr2 Emax (%) |
5 | 1.0 | 51 | 4.0 | 62 |
6 | Inactive | <20 | 1.6 | 47 |
7 | Inactive | <20 | 50 | 97 |